Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method

Yaoxue Xuebao

Volumn 42, Issue 6, 2007, Pages 589-594

  Gao, Zhi Wei ^a   Shi, Xiao Jin ^a   Yu, Chen ^b   Li, Shui Jun ^b   Zhong, Ming Kang ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Xuhui Central Hospital   (China)

Author keywords

Cytochrome P 450; LC MS MS; Liver microsomes

Indexed keywords

CYTOCHROME P450; ENZYME INHIBITOR;

ARTICLE; DRUG ANTAGONISM; HUMAN; IC 50; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; TANDEM MASS SPECTROMETRY;

EID: 34547452296     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Yin OQ, Lam SS, Lo CM, et al. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies [J]. Rapid Commun Mass Spectrom, 2004,18: 2921-2933.
2. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data [J]. Nat Rev Drug Discov, 2005,4:825-833.
3. Yin H, Racha J, Li SY, et al. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method; application in CYP inhibition evaluation [J]. Xenobiotica, 2000,30:141-154.
4. Bu HZ, Magis L, Knuth K, et al. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy. I. Development of direct injection/ on-line guard cartridge extraction/tandem mass spectrometry for the simultaneous detection of CYP probe substrates and their metabolites [J]. Rapid Commun Mass Spectrom, 2000,14:1619-1624.
5. Dierks EA, Stams KR, Lim HK, et al. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry [J]. Drug Metab Dispos, 2001,29:23-29.
6. Zhang T, Zhu Y, Gunaratna C. Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry [J]. J Chromatogr B, 2002,780:371-379.
7. Testino SA, Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry [J]. J Pharm Biomed Anal, 2003, 30:1459-1467.
8. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction [J]. Rapid Commun Mass Spectrom, 2004, 18:2273-2281.
9. Turpeinen M, Uusitalo J, Jalonen J, et al. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay [J]. Eur J Pharm Sci, 2005,24: 123-132.
10. Lake B. Preparation and Characterization of Microsomal Fractions for Studies on Xenobiotic Metabolism [M]. London: IRL Press, 1987:183-215.
11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding [J]. Anal Biochem, 1976,2:248-254.
12. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities [J]. Drug Metab Dispos, 2004,32:647-660.
13. Andersson TB, Bredberg E, Ericsson H, et al. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates [J]. Drug Metab Dispos, 2004,32: 715-721.
14. Bu HZ, Knuth K, Magis L, et al. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment [J]. Eur J Pharm Sci, 2001,12:447-452.
15. Scott RJ, Palmer J, Lewis IA, et al. Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry [J]. Rapid Commun Mass Spectrom, 1999,13:2305-2319.
16. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective [J]. J Clin Pharmcol, 2003,43:443-469.
17. Margolis JM, Obach RS. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6; implications for relating in vitro inhibition data to in vivo drug interactions [J]. Drug Metab Dispos, 2003,31:606-611.
18. Tran TH, Von Moltke LL, Venkatakrishnan K, et al. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors [J]. Drug Metab Dispos, 2002,30:1441-1445.
19. Li J, Wen SY, Wang R, et al. Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray [J]. Acta Pharm Sin, 2005, 40:695-699.